Adaptive Biotechnologies Corporation (NASDAQ: ADPT) announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock by certain selling shareholders at a public offering price of$26.50per share, before underwriting discounts and commissions. In addition,the selling shareholders have granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. Adaptive will not receive any proceeds from the sale of the shares of common stock by the selling shareholders. The offering is expected to close onJanuary 28, 2020, subject to customary closing conditions.
J.P. Morgan, Goldman Sachs & Co. LLC and BofA Securities are acting as joint lead book-running managers for the offering. Cowen, Guggenheim Securities and William Blair are acting as book-running managers for the offering. BTIG is acting as co-manager for the offering.